A Syringe of Methylprednisolone and a Six-Year Ban: The Murder of a Medical Ledger in the Ruti Aga Case

Reading the Ruti Aga case, I pulled out my old Pune ledger. In 2026 I used to shout the PPDA number from the Balewadi stand, and the habit has not left me — number first, story second. In this case one set of numbers decides everything else: two years for presence, four for tampering. Six years. At thirty-two, that is the end of Aga's elite career, and what stings me as a reporter is not that she was found culpable — it is that the thing that doubled her sanction was not a drug. It was a piece of paper.

Start with the factual frame every report should carry and this case demands. Aga won a half marathon in China in March — no time, no splits, no field strength are given in the text. So I will not write a word about her form; 'won' tells me only that the race carried an AIU testing window. Then came the knee-injury explanation, and in support of it a prescription was produced — and found to be fabricated. She has been provisionally suspended since 10 September, and the six-year ban runs from there. The 2026 Tokyo Marathon title and three World Marathon Majors second places are her actual record, and the source nowhere states the scope of disqualification.

Here is my first irritation, and it belongs to journalism, not the athlete. Several reports labelled methylprednisolone a 'steroid.' Wrong. It is a glucocorticoid, class S9 on the WADA list, and S9 is prohibited in-competition only — by injection, oral or rectal route. The whole fight was never 'steroid or not'; it was route and timing. A therapeutic knee injection is entirely legal out of competition and becomes a violation only if residues are present in-competition. Intra-articular methylprednisolone for knee synovitis is routine sports medicine for a distance runner. Which is precisely why the question is: with a legitimate defence available, why forge the paper?

I have one answer, and it is economics, not pharmacology. Aga races in an economy where income is appearance fees and Major prize money, not a pro-league contract. After Tokyo 2026 her pattern was selective Majors with Asian label races between them. The model pays well and carries one flaw: an injury uninsured. When the knee gives way, the fee gives way with it. Hiding pain with a cheap, available glucocorticoid is the obvious tool.

And this is where the ledger shows the real fault line. The prescription came from a clinic that did not exist, issued by a person with no medical registration — a family member who claimed an 'old prescription pad' that the clinic explicitly disowned. Three independent verification failures. That is not a filing error; it is the signature of an athlete running without a credentialed team physician. Since 2026 I have covered selection trials, from Kerala middle-distance camps to Haryana javelin akhadas, and the biggest inequality I have seen is not talent. It is medical support — the big camps have a doctor, a physio and a TUE file in one room; getting there is itself a form.

One TUE document, which would have made this entire case disappear, was replaced by a forged prescription — and that difference priced the athlete's future.

Now the part where I fight my own habit. My byline is counter-intuitive discovery. But sometimes the plain reading is correct, and here it is: six years looks harsh, yet look at the arithmetic. Two years for presence means the panel likely rejected no-fault or no-significant-fault mitigation. Four years for tampering is the Code's standard. Two plus four, six. That is not inconsistency; that is the framework. I will not sell this as 'disproportionate action against African road runners' — I do not have my own ledger of comparable cases to make that claim, and a number I have not reconciled myself is a number I do not print.

But one systemic point stands. A six-year ban for a substance with no proven endurance benefit, and 'tampering' recurring across AIU East African road-racing cases, tells us the enforcement frontier has shifted from detection to document verification. The investigation now reads paperwork more than samples. China's label-race circuit — big appearance budgets, deep East African elite fields, and now AIU attention — is where the fee economy and the testing economy collide on the same track.

And the sampling note I attach to every data-led piece: this ledger cannot see what was never recorded. Here that is the March race time, its splits, field depth, the scope of disqualification, and a single line on the agent's or management's role. The AIU statement names only the family member. Someone advised or watched that prescription being made — that question sits in my ledger as a blank page.

What next? An appeal window is open, but document-based findings are hard to overturn. Ethiopia's women's marathon depth is such that a 38-year-old return is nearly impossible — a 2:18 performer is not automatically selected there. The question is not whether Aga comes back. It is how many more athletes in her training clusters are running on the same informal medical network, whose only verifiable document is now in a courtroom — and the next time a knee gives way, will there be a TUE, or another old prescription pad?